Joshua R. Disbrow - 14 Jun 2023 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Role: Chief Executive Officer, Director
Signature: /s/ Mark Oki as attorney-in-fact for Joshua R. Disbrow
Issuer symbol: AYTU
Transactions as of: 14 Jun 2023
Transactions value $: $26,079
Form type: 4
Date filed: 15 Jun 2023, 13:52
Previous filing: 23 Dec 2022
Next filing: 16 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AYTU	Common Shares	Purchase	$26.1K	+14K	+24.31%	$1.86	71.6K	14 Jun 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The purchase price reported in Column 4 above is an average weighted price. These shares were purchased in multiple transactions at prices ranging from $1.79 to $1.87, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2	Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023.

Content

The purchase price reported in Column 4 above is an average weighted price. These shares were purchased in multiple transactions at prices ranging from $1.79 to $1.87, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023.